{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-044240","form_type":"8-K","ticker":"PTPI","cik":"0001815903","company_name":"Petros Pharmaceuticals, Inc.","filed_at":"2025-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.842485+00:00","generated_at":"2026-05-22T23:01:43.348520+00:00","sec_items":["3.01","3.03","5.03","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Petros gets additional Nasdaq delisting notice for Feb 2025 offering; completes 1-for-25 reverse split","bullets":["Nasdaq notified Petros on April 28 of public interest concerns regarding its February 19, 2025 public offering as a new delisting basis under Rule 5810(d).","Company intends to address concerns before a Nasdaq Hearings Panel; delisting actions are stayed pending the hearing.","1-for-25 reverse stock split effective 4:05 pm ET April 30, 2025; split-adjusted trading began May 1, 2025, under same symbol PTPI.","No fractional shares issued; authorized shares remain 7 billion; proportionate adjustments made to options and equity plan.","New CUSIP number is 71678J308; the reverse split does not immediately affect trading."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-044240","json":"https://secwatch.observer/filing/0001104659-25-044240.json","markdown":"https://secwatch.observer/filing/0001104659-25-044240.md","text":"https://secwatch.observer/filing/0001104659-25-044240.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815903/000110465925044240/0001104659-25-044240-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815903/000110465925044240/tm2513449d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T23:01:43.348520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21e960e6b1e1369940910ff330be472f5866ad79","claim":"Petros Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other (rules 5810(c)(3)(A)(iii), 5810(d)).","evidence_excerpt":"April 28, 2025, Nasdaq notified the Company (the “ Notice ”) it had public interest concerns regarding the Company’s public offering of securities that closed on February 19, 2025, which serves as an additional basis for delisting the Company’s securities pursuant to Nasdaq Listing Rule 5810(d). The Company intends to address these concerns before a Nasdaq Hearings Panel (the “ Panel ”). As a result of the Company’s hearing request pending appeal notice, all delisting actions have been stayed, pending a hearing before the Panel. The Notice has no immediate impact on the Company’s common stock","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815903/000110465925044240/0001104659-25-044240-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Rules","value":"5810(c)(3)(A)(iii), 5810(d)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}